Bug-brain axis
Why Axial is targeting the gut microbiome to treat CNS disorders
Investors supplied Axial Biotherapeutics Inc. with enough cash to get human proof of concept showing that correcting microbiome imbalances can treat pathologies and symptoms of neurological disorders.
The newco debuted Nov. 30 with a $19.2 million series A co-led by Longwood Fund and
